ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
ANAPTYSBIO, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on May 12, 2026
$49.24+2.63 (+5.64%)
Close on Oct 19, 2026
- Market cap
- $2.28B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
30M of 30M shares
Institutional holders
213
46 new, 37 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 41 sales
Net sold $9.50M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Oleg Nodelman | 7,794,996 | 25.80% | 13D (active) amendment | Aug 14, 2024 |
| Tang Capital Management, LLC | 1,950,609 | 7.30% | 13G (passive) amendment | Dec 31, 2023 |
| Alex Silverstein | 1,920,402 | 6.70% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 1,900,844 | 6.20% | 13G (passive) amendment | Mar 31, 2025 |
| Steven A. Cohen | 1,691,372 | 5.60% | 13G (passive) | Feb 14, 2025 |
| Sirenia Capital Management LP | 1,491,959 | 5.00% | 13G (passive) amendment | Jun 30, 2026 |
| Millennium Group Management LLC | 1,426,893 | 5.10% | 13G (passive) | Sep 16, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ANAB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 7,880,094 | 26.36% | $531.91M | – | 25.86% |
| BlackRock, Inc. | 1,844,049 | 6.17% | $124.47M | +162,669 | 0.00% |
| Tang Capital Management LLC | 1,330,879 | 4.45% | $89.83M | – | 4.08% |
| State Street Corp | 1,286,194 | 4.30% | $86.82M | +293,749 | 0.00% |
| Vanguard Capital Management LLC | 906,233 | 3.03% | $61.17M | +53,082 | 0.00% |
| Affinity Asset Advisors, LLC | 826,109 | 2.76% | $55.76M | −113,891 | 2.52% |
| Sanofi | 821,917 | 2.75% | $55.48M | – | 10.39% |
| Millennium Management LLC | 807,316 | 2.70% | $54.49M | +331,744 | 0.02% |
| Woodline Partners LP | 717,014 | 2.40% | $48.40M | +372,758 | 0.15% |
| 683 Capital Management, LLC | 660,000 | 2.21% | $44.55M | +35,000 | 2.19% |
| Geode Capital Management, LLC | 637,873 | 2.13% | $43.06M | +117,632 | 0.00% |
| Palo Alto Investors LP | 603,489 | 2.02% | $40.74M | −34,672 | 5.63% |
| Goldman Sachs Group Inc | 584,070 | 1.95% | $39.42M | +251,327 | 0.00% |
| First Light Asset Management, LLC | 582,004 | 1.95% | $39.29M | +16,573 | 2.39% |
| D. E. Shaw & Co., Inc. | 539,666 | 1.81% | $36.43M | −39,630 | 0.02% |
| Vanguard Portfolio Management LLC | 527,858 | 1.77% | $35.63M | +7,988 | 0.00% |
| Apis Capital Advisors, LLC | 497,000 | 1.66% | $33.55M | +259,000 | 3.27% |
| Sofinnova Investments, Inc. | 493,536 | 1.65% | $33.31M | +245,283 | 1.72% |
| Arrowstreet Capital, Limited Partnership | 488,651 | 1.63% | $32.98M | −3,469 | 0.01% |
| Nuveen, LLC | 420,664 | 1.41% | $28.39M | +104,599 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 213 | 30M | 100.0% | 46 / 73 | 65 / 37 | 5M | 3M |
| Q1 2026 | 208 | 28M | 94.5% | 51 / 59 | 70 / 20 | 5M | 5M |
| Q4 2025 | 179 | 29M | 98.2% | 37 / 51 | 64 / 24 | 3M | 5M |
| Q3 2025 | 166 | 32M | 100.0% | 35 / 43 | 59 / 15 | 5M | 9M |
| Q2 2025 | 147 | 37M | 100.0% | 27 / 46 | 54 / 31 | 5M | 9M |
| Q1 2025 | 153 | 40M | 100.0% | 45 / 44 | 43 / 26 | 13M | 8M |
| Q4 2024 | 135 | 35M | 100.0% | 27 / 50 | 35 / 52 | 8M | 6M |
| Q3 2024 | 160 | 34M | 100.0% | 38 / 61 | 31 / 11 | 8M | 2M |
| Q2 2024 | 135 | 30M | 99.7% | 26 / 43 | 45 / 23 | 6M | 7M |
| Q1 2024 | 133 | 31M | 100.0% | 26 / 41 | 40 / 12 | 4M | 4M |
| Q4 2023 | 119 | 31M | 100.0% | 16 / 32 | 43 / 13 | 4M | 3M |
| Q3 2023 | 116 | 30M | 100.0% | 14 / 34 | 38 / 14 | 4M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ANAB | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 786,627 | 2.63% | $53.10M | 0.49% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 648,146 | 2.17% | $43.75M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 514,945 | 1.72% | $34.76M | 0.04% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 263,840 | 0.88% | $14.08M | 0.35% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 237,032 | 0.79% | $16.00M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 215,873 | 0.72% | $11.52M | 0.03% | Jul 31, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 210,000 | 0.70% | $11.21M | 0.39% | Jul 31, 2026 |
| iShares Biotechnology ETF | 193,528 | 0.65% | $13.06M | 0.14% | Jun 30, 2026 |
| Victory Science & Technology Fund | 187,893 | 0.63% | $10.03M | 0.67% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 185,548 | 0.62% | $12.52M | 0.08% | Jun 30, 2026 |
| Burney U.S. Equity Select ETF | 148,943 | 0.50% | $7.95M | 1.18% | Jul 31, 2026 |
| Vanguard Strategic Equity Fund | 131,265 | 0.44% | $8.86M | 0.07% | Jun 30, 2026 |
| First Trust Small Cap Growth AlphaDEX Fund | 130,011 | 0.43% | $6.94M | 0.53% | Jul 31, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 127,704 | 0.43% | $6.81M | 0.30% | Jul 31, 2026 |
| Burney U.S. Factor Rotation ETF | 123,969 | 0.41% | $6.61M | 1.14% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Daniel Faga | President, CEO, Director | 510,564 | 1.71% | Aug 7, 2026 |
| Paul F. Lizzul | Chief Medical Officer | 42,088 | 0.14% | Aug 7, 2026 |
| Christopher M. Murphy | Chief Financial Officer | – | – | May 13, 2026 |
| Eric J. Loumeau | CHIEF LEGAL OFFICER | 12,835 | 0.04% | Feb 13, 2026 |
| Dennis Mulroy | CHIEF FINANCIAL OFFICER | 21,852 | 0.07% | Jan 9, 2026 |
| John A. Orwin | Director | 17,995 | 0.06% | Sep 17, 2026 |
| John P. Schmid | Director | 37,652 | 0.13% | Jun 17, 2026 |
| Hollings Renton | Director | 10,995 | 0.04% | Jun 17, 2026 |
| Owen Hughes | Director | – | – | May 13, 2026 |
| Susannah Gray | Director | – | – | Apr 29, 2026 |
| Magda Marquet | Director | 20,930 | 0.07% | Jan 16, 2026 |
| J. Anthony Ware | Director | 9,630 | 0.03% | Jan 8, 2026 |
| Rita Jain | Director | 11,864 | 0.04% | Jan 8, 2026 |
| Dennis M. Fenton | Director | 4,965 | 0.02% | Jan 8, 2026 |
| EcoR1 Capital, LLC | Director, 10% owner | 7,880,094 | 26.36% | Jan 2, 2025 |
| Oleg Nodelman | Director, 10% owner | 7,520,424 | 25.16% | Jan 2, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John A. Orwin Director | Sep 15, 2026 | Option exercise | +1,300 | – | – | 17,995 |
| John A. Orwin Director | Jun 15, 2026 | Option exercise | +6,030 | – | – | 16,695 |
| John P. Schmid Director | Jun 15, 2026 | Option exercise | +6,030 | – | – | 37,652 |
| Hollings Renton Director | Jun 15, 2026 | Option exercise | +6,030 | – | – | 10,995 |
| John P. Schmid Director | Mar 30, 2026 | Sale | −522 | $57.40 | $29.96K | 31,622 |
| John P. Schmid Director | Mar 30, 2026 | Sale | −7,527 | $56.70 | $426.78K | 32,144 |
| John P. Schmid Director | Mar 30, 2026 | Sale | −12,596 | $55.71 | $701.72K | 39,671 |
| Daniel Faga President, CEO, Director | Mar 27, 2026 | Sale | −2,570 | $57.91 | $148.83K | 510,564 |
| Daniel Faga President, CEO, Director | Mar 27, 2026 | Sale | −510 | $56.61 | $28.87K | 513,134 |
| Daniel Faga President, CEO, Director | Mar 27, 2026 | Sale | −3,662 | $58.62 | $214.67K | 506,902 |
| Daniel Faga President, CEO, Director | Mar 27, 2026 | Sale | −490 | $59.62 | $29.21K | 506,412 |
| Daniel Faga President, CEO, Director | Mar 27, 2026 | Sale | −550 | $60.63 | $33.35K | 505,862 |
| Daniel Faga President, CEO, Director | Mar 27, 2026 | Sale | −1,012 | $62.15 | $62.90K | 504,850 |
| Daniel Faga President, CEO, Director | Mar 27, 2026 | Sale | −2,592 | $63.35 | $164.20K | 502,258 |
| Daniel Faga President, CEO, Director | Mar 27, 2026 | Sale | −3,155 | $64.19 | $202.52K | 499,103 |
| Daniel Faga President, CEO, Director | Mar 27, 2026 | Sale | −3,038 | $65.20 | $198.08K | 496,065 |
| Daniel Faga President, CEO, Director | Mar 27, 2026 | Sale | −100 | $65.99 | $6.60K | 495,965 |
| Daniel Faga President, CEO, Director | Mar 25, 2026 | Award | +34,300 | – | – | 513,644 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Feb 11, 2026 | Sale(10b5-1 plan) | −10,000 | $54.00 | $540.00K | 12,835 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Feb 11, 2026 | Option exercise | +10,000 | $29.70 | $297.00K | 22,835 |
| Magda Marquet Director | Jan 15, 2026 | Option exercise | +11,000 | $26.11 | $287.21K | 20,930 |
| Magda Marquet Director | Jan 15, 2026 | Sale | −1,710 | $48.85 | $83.53K | 9,930 |
| Magda Marquet Director | Jan 15, 2026 | Sale | −9,290 | $48.12 | $447.03K | 11,640 |
| Daniel Faga President, CEO, Director | Jan 8, 2026 | Sale | −14,281 | $44.71 | $638.50K | 479,344 |
| Dennis Mulroy CHIEF FINANCIAL OFFICER | Jan 8, 2026 | Sale | −2,515 | $44.71 | $112.45K | 21,852 |
| Paul F. Lizzul Chief Medical Officer | Jan 8, 2026 | Sale | −3,650 | $44.71 | $163.19K | 42,088 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Jan 8, 2026 | Sale | −2,210 | $44.71 | $98.81K | 12,835 |
| Daniel Faga President, CEO, Director | Jan 7, 2026 | Option exercise | +26,838 | – | – | 493,625 |
| Dennis Mulroy CHIEF FINANCIAL OFFICER | Jan 7, 2026 | Option exercise | +6,700 | – | – | 24,367 |
| Paul F. Lizzul Chief Medical Officer | Jan 7, 2026 | Option exercise | +8,525 | – | – | 45,738 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Jan 7, 2026 | Option exercise | +5,888 | – | – | 15,045 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Jan 7, 2026 | Sale(10b5-1 plan) | −1,841 | $46.13 | $84.93K | 9,657 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Jan 7, 2026 | Sale(10b5-1 plan) | −500 | $47.23 | $23.62K | 9,157 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Jan 7, 2026 | Sale(10b5-1 plan) | −5,281 | $45.38 | $239.65K | 11,498 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Jan 7, 2026 | Sale(10b5-1 plan) | −2,017 | $45.11 | $90.99K | 16,779 |
| Dennis Mulroy CHIEF FINANCIAL OFFICER | Jan 7, 2026 | Sale | −1,908 | $45.11 | $86.07K | 17,667 |
| Paul F. Lizzul Chief Medical Officer | Jan 7, 2026 | Sale | −2,235 | $45.11 | $100.82K | 37,213 |
| Daniel Faga President, CEO, Director | Jan 7, 2026 | Sale | −9,202 | $45.11 | $415.10K | 466,787 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Jan 6, 2026 | Option exercise | +5,545 | – | – | 18,796 |
| Dennis Mulroy CHIEF FINANCIAL OFFICER | Jan 6, 2026 | Option exercise | +5,245 | – | – | 19,575 |
| Paul F. Lizzul Chief Medical Officer | Jan 6, 2026 | Option exercise | +6,145 | – | – | 39,448 |
| Daniel Faga President, CEO, Director | Jan 6, 2026 | Option exercise | +17,850 | – | – | 475,989 |
| Paul F. Lizzul Chief Medical Officer | Jan 5, 2026 | Sale | −4,219 | $43.26 | $182.51K | 33,303 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Jan 5, 2026 | Sale | −2,983 | $43.26 | $129.04K | 13,251 |
| Daniel Faga President, CEO, Director | Jan 5, 2026 | Sale | −15,309 | $43.26 | $662.27K | 458,139 |
| Dennis Mulroy CHIEF FINANCIAL OFFICER | Jan 5, 2026 | Sale | −3,363 | $43.26 | $145.48K | 14,330 |
| Paul F. Lizzul Chief Medical Officer | Jan 3, 2026 | Option exercise | +10,555 | – | – | 37,522 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Jan 3, 2026 | Option exercise | +7,287 | – | – | 16,234 |
| Daniel Faga President, CEO, Director | Jan 3, 2026 | Option exercise | +34,677 | – | – | 473,448 |
| Dennis Mulroy CHIEF FINANCIAL OFFICER | Jan 3, 2026 | Option exercise | +8,292 | – | – | 17,693 |
| J. Anthony Ware Director | Dec 23, 2025 | Sale | −3,900 | $49.58 | $193.36K | 9,630 |
| John P. Schmid Director | Dec 23, 2025 | Other | −11,068 | $51.00 | $564.47K | 0 |
| Paul F. Lizzul Chief Medical Officer | Dec 22, 2025 | Sale(10b5-1 plan) | −1,500 | $50.00 | $75.00K | 26,967 |
| Paul F. Lizzul Chief Medical Officer | Dec 22, 2025 | Option exercise | +1,500 | $18.50 | $27.75K | 28,467 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Dec 22, 2025 | Option exercise | +10,000 | $14.02 | $140.20K | 18,947 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Dec 22, 2025 | Sale(10b5-1 plan) | −10,000 | $51.00 | $510.00K | 8,947 |
| Dennis Mulroy CHIEF FINANCIAL OFFICER | Dec 22, 2025 | Option exercise | +10,000 | $20.16 | $201.60K | 19,401 |
| Dennis Mulroy CHIEF FINANCIAL OFFICER | Dec 22, 2025 | Sale(10b5-1 plan) | −10,000 | $50.00 | $500.00K | 9,401 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Dec 18, 2025 | Sale(10b5-1 plan) | −141 | $46.99 | $6.63K | 8,947 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Dec 17, 2025 | Option exercise | +10,000 | $14.02 | $140.20K | 19,088 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| C. Renton Hollings Director | Oct 1, 2026 | 5,000 | $249.37K | Oct 1, 2026 | Stock Option Exercise |
| Anthony Ware Joe Director | Jul 13, 2026 | 10,694 | $718.33K | Jul 13, 2026 | Stock Option Exercise |
| Anthony Ware Joe Director | Jun 30, 2026 | 6,030 | $408.77K | Jun 30, 2026 | Restricted Stock |
| Mulroy Dennis Officer | Jun 29, 2026 | 9,476 | $601.21K | Jun 29, 2026 | Stock Option Exercise |
| Mulroy Dennis Officer | Jun 26, 2026 | 10,000 | $608.18K | Jun 26, 2026 | Stock Option Exercise |
| Mulroy Dennis Officer | Jun 17, 2026 | 850 | $51.00K | Jun 17, 2026 | Stock Option Exercise |
| Mulroy Dennis Officer | Jun 16, 2026 | 1,265 | $75.90K | Jun 16, 2026 | Stock Option Exercise |
| Mulroy Dennis Officer | Jun 15, 2026 | 20,000 | $1.15M | Jun 15, 2026 | Stock Option Exercise |
| Mulroy Dennis Officer | Jun 12, 2026 | 20,000 | $1.11M | Jun 12, 2026 | Stock Option Exercise |
| Mulroy Dennis Officer | Jun 11, 2026 | 35,000 | $1.85M | Jun 11, 2026 | Stock Option Exercise |
| Mulroy Dennis Officer | Jun 10, 2026 | 20,000 | $1.05M | Jun 10, 2026 | Stock Option Exercise |
| Mulroy Dennis Officer | Jun 9, 2026 | 20,000 | $1.03M | Jun 9, 2026 | Stock Option Exercise |
| Mulroy Dennis Officer | Jun 8, 2026 | 21,987 | $1.12M | Jun 8, 2026 | Restricted Stock |
| Mulroy Dennis Officer | Jun 5, 2026 | 22,491 | $1.15M | Jun 5, 2026 | Stock Option Exercise |
| Mulroy Dennis Officer | Jun 5, 2026 | 20,000 | $1.04M | Jun 4, 2026 | Stock Option Exercise |